Civeo (NYSE:CVEO) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$162.7m (down 14% from 2Q 2024).
• Net loss: US$3.31m (down by 140% from US$8.23m profit in 2Q 2024).
• US$0.25 loss per share (down from US$0.57 profit in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Civeo EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 79%.

Looking ahead, revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Commercial Services industry in the US.

Performance of the American Commercial Services industry.

The company's shares are down 2.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Civeo that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.